Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Debt-to-Equity Related Terms
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Debt-to-Equity Chart
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Annual Data
IST:GENIL vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Debt-to-Equity vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) has a Debt-to-Equity of 0.41 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. This is 86% above median its historical median of 0.22. Over the past decade, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Debt-to-Equity has ranged from 0.11 to 1.50. According to the industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #506 out of 813 companies in the Drug Manufacturers industry, placing it in the top 62.2%.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Debt-to-Equity too high?
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current Debt-to-Equity of 0.41 is 86% above median its 10-year median of 0.22. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 1.50. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 0.41 is 51.9% above this industry median. Based on the distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #506 out of 813 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #506 out of 813 companies for Debt-to-Equity. This places Gen Ilac Veglik Urunlerinayi ve Ticaret AS in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 0.41 is 51.9% above this benchmark. Historically, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's own Debt-to-Equity has ranged from 0.11 to 1.50 over the past decade. While the company's 10-year median is 0.22 vs. the industry median of 0.27, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current Debt-to-Equity of 0.41 is 51.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current Debt-to-Equity is 0.41, which is 86% above median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₺8.22, compared to a current price of ₺9.36 — trading 13.9% above its estimated fair value. The current Debt-to-Equity is 0.41, which is 86% above median its 10-year median of 0.22 and 51.9% above the Drug Manufacturers industry median of 0.27. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL), the current Debt-to-Equity is 0.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Overvalued in 2026?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺9.36 is trading 13.9% above its estimated GF Value™ of ₺8.22.
GuruFocus considers Gen Ilac Veglik Urunlerinayi ve Ticaret AS to be Modestly Overvalued.
Key valuation signals for IST:GENIL:
Debt-to-Equity: 0.41 (86% above median its 10-year median of 0.22)
GF Value™: ₺8.22 vs. price of ₺9.36 (13.9% above fair value)
Industry Position: 51.9% above the Drug Manufacturers median (#506 of 813)
No single metric tells the full story. See the IST:GENIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Business Description
Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS is a specialty pharmaceuticals company in Turkey. Its locally manufactured products include Cajex, Contra-K, Epamor, Genkort, Ilopera, among others, while imported products include AvonexPEN, Plegridy, Tecfidera, Regen-D among others.
87GF Score
Get the complete analysis for IST:GENIL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:GENIL has been successfully added to your 
